1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,050 | 5,280 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 29.01. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT OF ESTIMATED ANNUAL RESULTS FOR THE YEAR 2025 | 3 | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR; AND NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 26.01. | BIOCYTOGEN-B (02315): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 4 | HKEx | ||
| 12.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT EXPANDED COLLABORATION WITH ACEPODIA THROUGH OPTION-BASED EVALUATION FRAMEWORK FOR FIRST-IN-CLASS DUAL-PAYLOAD ... | 1 | HKEx | ||
| 09.01. | Biocytogen und Acepodia erweitern Kooperation durch optionsbasiertes Evaluierungsmodell für bispezifische und Dual-Payload-First-in-Class-ADC (BsAD2C) | 441 | Business Wire | Die erweiterte Zusammenarbeit knüpft an die jüngsten gemeinsamen Entwicklungsanstrengungen von Acepodia und Biocytogen zur Evaluierung ausgewählter bispezifischer Antikörper- und Dual-Payload-ADC-Programme... ► Artikel lesen | |
| 09.01. | Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C) | 292 | Business Wire | Expanded collaboration builds on Acepodia and Biocytogen's recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs
Biocytogen Pharmaceuticals (Beijing)... ► Artikel lesen | |
| 31.12.25 | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 31.12.25 | BIOCYTOGEN-B (02315): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 24.12.25 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT INCLUSION IN THE STOCK LIST UNDER THE STOCK CONNECT | 2 | HKEx | ||
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Börsengang am STAR-Markt ab und wird zum ersten globalen Arzneimittelentwickler mit "H+A"-Status | 518 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das innovative Arzneimittelforschung vorantreibt, gab heute seine... ► Artikel lesen | |
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 541 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing... ► Artikel lesen | |
| 10.12.25 | BIOCYTOGEN-B (02315): NEXT DAY DISCLOSURE RETURNS | 4 | HKEx | ||
| 10.12.25 | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 551 | Business Wire | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful... ► Artikel lesen | |
| 10.12.25 | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE STRATEGY COMMITTEE | 2 | HKEx | ||
| 10.12.25 | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE REMUNERATION AND EVALUATION COMMITTEE | 2 | HKEx | ||
| 09.12.25 | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 09.12.25 | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE AUDIT COMMITTEE | 1 | HKEx |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,042 | -8,26 % | Medigene: Zurückziehung - 18.11.2025 | ||
| BIOFRONTERA | 2,420 | -1,22 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| CLINUVEL | 6,485 | +0,31 % | CLINUVEL PHARMACEUTICALS LIMITED: Clinical & Financial Update | ||
| EDITAS MEDICINE | 1,536 | +0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| ASEP MEDICAL | 0,135 | 0,00 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,100 | +9,93 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,352 | -0,44 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC | - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in... ► Artikel lesen | |
| CLEAN HARBORS | 228,30 | +1,47 % | Reasons Why You Should Retain Clean Harbors Stock in Your Portfolio | ||
| LIR LIFE SCIENCES | 0,844 | -2,09 % | EQS-Media: First-Mover mit erheblichem Skalierungspotenzial: LIR Life Sciences setzt Innovations-Roadmap fort | EQS-Media / 06.02.2026 / 16:20 CET/CEST
LIR Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), LIR oder das Unternehmen, freut sich bekannt zu geben, dass es mit "Neuland Laboratories Limited"... ► Artikel lesen | |
| MESOBLAST | 1,290 | -3,01 % | Von der Vision zum Wert: Mesoblast etabliert sich als führendes Unternehmen der globalen Biotechnologie. Teil der ASX "Big Three" zusammen mit CSL und Telix. | ||
| SPERO THERAPEUTICS | 2,030 | 0,00 % | Anterix Inc.: Anterix Appoints Ross Spero as Chief Product Officer | WOODLAND PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Anterix, Inc. (NASDAQ: ATEX) today announced the appointment of Ross Spero as Chief Product Officer. Spero will lead Anterix's product development... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,535 | -1,83 % | CSTONE PHARMA-B (02616): UPDATE ON THE QUALIFICATION OF JOINT COMPANY SECRETARY AND CHANGE OF COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE | ||
| PROTALIX BIOTHERAPEUTICS | 2,420 | -0,82 % | Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) in the EU | Committee
for
Medicinal
Products
for
Human
Use
(CHMP)
issues
a
positive
opinion following re-examination, which
will
be reviewed by
the... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 65,00 | -7,14 % | Palvella Therapeutics: Clear Street bestätigt Kaufempfehlung im Vorfeld von Studiendaten | ||
| PURPLE BIOTECH | 0,600 | +0,42 % | Purple Biotech Ltd.: Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update | Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform... ► Artikel lesen |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,100 (+2,02 %) liegt der Kurs bei 5,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.